Balyasny Asset Management
XENT

Balyasny Asset Management’s Intersect ENT, Inc XENT Stock Holding History

Balyasny Asset Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-205,600
Closed -$6.03M – 1885
2018
Q3 		$6.03M Buy
+205,600
New +$6.18M 0.03% 640

Other funds holding XENT

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

Balyasny Asset Management's XENT Position: Q2 2021 in Review

Balyasny Asset Management sold out of Intersect ENT, Inc (XENT) in Q2 2021, closing a stake of 300,103 shares — an estimated $6.27M sold.

Balyasny Asset Management first reported a position in XENT in Q3 2015 and held it in 13 quarters. The position peaked at $9.21M in Q4 2020. 107 funds tracked by Wall St. Rank hold XENT as of Q2 2021.

  • Balyasny Asset Management reported no remaining Intersect ENT, Inc position as of Q2 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 300,103 Intersect ENT, Inc shares in Q2 2021, an estimated $6.27M.
  • Balyasny Asset Management first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 13 quarters.
  • Balyasny Asset Management's Intersect ENT, Inc position peaked at $9.21M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.